Bone marrow endothelium-targeted therapeutics for metastatic breast cancer

Journal of Controlled Release

Volumn 187, Issue , 2014, Pages 22-29

  Mai, Junhua ^a   Huang, Yi ^a,d   Mu, Chaofeng ^a   Zhang, Guodong ^a   Xu, Rong ^a   Guo, Xiaojing ^a,e   Xia, Xiaojun ^a   Volk, David E ^b   Lokesh, Ganesh L ^b   Thiviyanathan, Varatharasa ^b   Gorenstein, David G ^b   Liu, Xuewu ^a   Ferrari, Mauro ^a,c   Shen, Haifa ^a,c  

^a HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d THIRD MILITARY MEDICAL UNIVERSITY   (China)

^e TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Bone metastasis; Breast cancer; E selectin; Silicon particle; Targeted siRNA delivery; Thioaptamer

Indexed keywords

BONE; CONTROLLED DRUG DELIVERY; DISEASES; ENDOTHELIAL CELLS; MAMMALS; PATHOLOGY; TISSUE ENGINEERING; TUMORS;

BONE METASTASIS; BREAST CANCER; SELECTINS; SILICON PARTICLES; SIRNA DELIVERY; THIOAPTAMER;

TARGETED DRUG DELIVERY;

1 (3 DIMETHYLAMINOPROPYL) 3 ETHYLCARBODIIMIDE; APTAMER; CD31 ANTIGEN; DRUG CARRIER; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; NANOPARTICLE; SILICON; SMALL INTERFERING RNA; STAT3 PROTEIN;

ADVANCED CANCER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW; BONE METASTASIS; BREAST CANCER; CANCER CELL LINE; CANCER GROWTH; CANCER INHIBITION; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG EFFICACY; EARLY CANCER; ENDOTHELIUM CELL; FEMALE; FEMUR; GENE EXPRESSION; GENE OVEREXPRESSION; GENE SILENCING; GENE TARGETING; GENE VECTOR; HUMAN; HUMAN CELL; MCF 7 CELL LINE; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SURVIVAL TIME; SYSTEMIC THERAPY; TISSUE DISTRIBUTION; TISSUE SPECIFICITY; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; ANIMAL; BONE NEOPLASMS; BREAST NEOPLASMS; CHEMISTRY; ENDOTHELIUM; GENETICS; METABOLISM; NUDE MOUSE; PATHOLOGY; SECONDARY; TUMOR CELL LINE;

ANIMALS; APTAMERS, NUCLEOTIDE; BONE MARROW; BONE NEOPLASMS; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG CARRIERS; E-SELECTIN; ENDOTHELIAL CELLS; ENDOTHELIUM; FEMALE; FEMUR; HUMANS; MCF-7 CELLS; MICE; MICE, NUDE; RNA, SMALL INTERFERING; SILICON; STAT3 TRANSCRIPTION FACTOR;

EID: 84901768538     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2014.04.057     Document Type: Article

References (45)

1. M. Smid, Y. Wang, Y. Zhang, A.M. Sieuwerts, J. Yu, J.G. Klijn, J.A. Foekens, and J.W. Martens Subtypes of breast cancer show preferential site of relapse Cancer Res. 68 9 2008 3108 3114
2. C. Liedtke, C. Mazouni, K.R. Hess, F. Andre, A. Tordai, J.A. Mejia, W.F. Symmans, A.M. Gonzalez-Angulo, B. Hennessy, M. Green, M. Cristofanilli, G.N. Hortobagyi, and L. Pusztai Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer J. Clin. Oncol. 26 8 2008 1275 1281
3. I.J. Diel, E.F. Solomayer, and G. Bastert Treatment of metastatic bone disease in breast cancer: bisphosphonates Clin. Breast Cancer 1 1 2000 43 51
4. G.R. Mundy Metastasis to bone: causes, consequences and therapeutic opportunities Nat. Rev. Cancer 2 8 2002 584 593 (Pubitemid 37328925)
5. M.S. Walker, P.J. Miller, M. Namjoshi, A.C. Houts, E.J. Stepanski, and L.S. Schwartzberg Relationship between incidence of fracture and health-related quality-of-life in metastatic breast cancer patients with bone metastasis J. Med. Econ. 16 1 2013 179 189
6. S.L. Hines, J.A. Sloan, P.J. Atherton, E.A. Perez, S.R. Dakhil, D.B. Johnson, P.S. Reddy, R.J. Dalton, B.I. Mattar, and C.L. Loprinzi Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy Breast 19 2 2010 92 96
7. D.H. Jones, T. Nakashima, O.H. Sanchez, I. Kozieradzki, S.V. Komarova, I. Sarosi, S. Morony, E. Rubin, R. Sarao, C.V. Hojilla, V. Komnenovic, Y.Y. Kong, M. Schreiber, S.J. Dixon, S.M. Sims, R. Khokha, T. Wada, and J.M. Penninger Regulation of cancer cell migration and bone metastasis by RANKL Nature 440 7084 2006 692 696
8. M. Martin, R. Bell, H. Bourgeois, A. Brufsky, I. Diel, A. Eniu, L. Fallowfield, Y. Fujiwara, J. Jassem, A.H. Paterson, D. Ritchie, G.G. Steger, A. Stopeck, C. Vogel, M. Fan, Q. Jiang, K. Chung, R. Dansey, and A. Braun Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid Clin. Cancer Res. 18 17 2012 4841 4849
9. R. Coleman, M. Gnant, G. Morgan, and P. Clezardin Effects of bone-targeted agents on cancer progression and mortality J. Natl. Cancer Inst. 104 14 2012 1059 1067
10. M. Gnant, B. Mlineritsch, G. Luschin-Ebengreuth, F. Kainberger, H. Kassmann, J.C. Piswanger-Solkner, M. Seifert, F. Ploner, C. Menzel, P. Dubsky, F. Fitzal, V. Bjelic-Radisic, G. Steger, R. Greil, C. Marth, E. Kubista, H. Samonigg, P. Wohlmuth, M. Mittlbock, and R. Jakesz Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy Lancet Oncol. 9 9 2008 840 849
11. T. Lorincz, J. Timar, and M. Szendroi Alterations of microvascular density in bone metastases of adenocarcinomas Pathol. Oncol. Res. 10 3 2004 149 153 (Pubitemid 39421993)
12. M.A. Moore Waking up hscs: a new role for E-selectin Nat. Med. 18 11 2012 1613 1614
13. A. Zarbock, K. Ley, R.P. McEver, and A. Hidalgo Leukocyte ligands for endothelial selectins: specialized glycoconjugates that mediate rolling and signaling under flow Blood 118 26 2011 6743 6751
14. I.G. Winkler, V. Barbier, B. Nowlan, R.N. Jacobsen, C.E. Forristal, J.T. Patton, J.L. Magnani, and J.P. Levesque Vascular niche E-selectin regulates hematopoietic stem cell dormancy, self renewal and chemoresistance Nat. Med. 18 11 2012 1651 1657
15. E. Jubeli, L. Moine, J. Vergnaud-Gauduchon, and G. Barratt E-selectin as a target for drug delivery and molecular imaging J. Control. Release 158 2 2012 194 206
16. M.J. Mitchell, C.S. Chen, V. Ponmudi, A.D. Hughes, and M.R. King E-selectin liposomal and nanotube-targeted delivery of doxorubicin to circulating tumor cells J. Control. Release 160 3 2012 609 617
17. E. Tasciotti, X. Liu, R. Bhavane, K. Plant, A.D. Leonard, B.K. Price, M.M. Cheng, P. Decuzzi, J.M. Tour, F. Robertson, and M. Ferrari Mesoporous silicon particles as a multistage delivery system for imaging and therapeutic applications Nat. Nanotechnol. 3 3 2008 151 157 (Pubitemid 351355132)
18. R. Xu, Y. Huang, J. Mai, G. Zhang, X. Guo, X. Xia, E.J. Koay, G. Qin, D.R. Erm, Q. Li, X. Liu, M. Ferrari, and H. Shen Multistage vectored sirna targeting ataxia-telangiectasia mutated for breast cancer therapy Small 9 9-10 2013 1799 1808
19. T. Tanaka, L.S. Mangala, P.E. Vivas-Mejia, R. Nieves-Alicea, A.P. Mann, E. Mora, H.D. Han, M.M. Shahzad, X. Liu, R. Bhavane, J. Gu, J.R. Fakhoury, C. Chiappini, C. Lu, K. Matsuo, B. Godin, R.L. Stone, A.M. Nick, G. Lopez-Berestein, A.K. Sood, and M. Ferrari Sustained small interfering RNA delivery by mesoporous silicon particles Cancer Res. 70 9 2010 3687 3696
20. H. Shen, C. Rodriguez-Aguayo, R. Xu, V. Gonzalez-Villasana, J. Mai, Y. Huang, G. Zhang, X. Guo, L. Bai, G. Qin, X. Deng, Q. Li, D.R. Erm, B. Aslan, X. Liu, J. Sakamoto, A. Chavez-Reyes, H.D. Han, A.K. Sood, M. Ferrari, and G. Lopez-Berestein Enhancing chemotherapy response with sustained EphA2 silencing using multistage vector delivery Clin. Cancer Res. 19 7 2013 1806 1815
21. A.P. Mann, T. Tanaka, A. Somasunderam, X. Liu, D.G. Gorenstein, and M. Ferrari E-selectin-targeted porous silicon particle for nanoparticle delivery to the bone marrow Adv. Mater. 23 36 2011 H278 H282
22. H. Shen, J. You, G. Zhang, A. Ziemys, Q. Li, L. Bai, X. Deng, D.R. Erm, X. Liu, C. Li, and M. Ferrari Cooperative, nanoparticle-enabled thermal therapy of breast cancer Adv. Healthc. Mater. 1 1 2012 84 89
23. P. Decuzzi, B. Godin, T. Tanaka, S.Y. Lee, C. Chiappini, X. Liu, and M. Ferrari Size and shape effects in the biodistribution of intravascularly injected particles J. Control. Release 141 3 2010 320 327
24. V. Mako, J. Czucz, Z. Weiszhar, E. Herczenik, J. Matko, Z. Prohaszka, and L. Cervenak Proinflammatory activation pattern of human umbilical vein endothelial cells induced by IL-1beta, TNF-alpha, and LPS Cytometry A 77 10 2010 962 970
25. J. Laferriere, F. Houle, and J. Huot Regulation of the metastatic process by E-selectin and stress-activated protein kinase-2/p38 Ann. N. Y. Acad. Sci. 973 2002 562 572 (Pubitemid 36125071)
26. L.L. Marotta, V. Almendro, A. Marusyk, M. Shipitsin, J. Schemme, S.R. Walker, N. Bloushtain-Qimron, J.J. Kim, S.A. Choudhury, R. Maruyama, Z. Wu, M. Gonen, L.A. Mulvey, M.O. Bessarabova, S.J. Huh, S.J. Silver, S.Y. Kim, S.Y. Park, H.E. Lee, K.S. Anderson, A.L. Richardson, T. Nikolskaya, Y. Nikolsky, X.S. Liu, D.E. Root, W.C. Hahn, D.A. Frank, and K. Polyak The JAK2/STAT3 signaling pathway is required for growth of CD44(+)CD24(-) stem cell-like breast cancer cells in human tumors J. Clin. Invest. 121 7 2011 2723 2735
27. Z. Chen, and Z.C. Han Stat3: a critical transcription activator in angiogenesis Med. Res. Rev. 28 2 2008 185 200 (Pubitemid 351281185)
28. C.A. O'Brien, I. Gubrij, S.C. Lin, R.L. Saylors, and S.C. Manolagas Stat3 activation in stromal/osteoblastic cells is required for induction of the receptor activator of NF-kappab ligand and stimulation of osteoclastogenesis by gp130-utilizing cytokines or interleukin-1 but not 1,25-dihydroxyvitamin d3 or parathyroid hormone J. Biol. Chem. 274 27 1999 19301 19308
29. K. Tawara, J.T. Oxford, and C.L. Jorcyk Clinical significance of interleukin (il)-6 in cancer metastasis to bone: potential of anti-IL-6 therapies Cancer Manag. Res. 3 2011 177 189
30. G. Dontu, W.M. Abdallah, J.M. Foley, K.W. Jackson, M.F. Clarke, M.J. Kawamura, and M.S. Wicha In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells Genes Dev. 17 10 2003 1253 1270 (Pubitemid 36583168)
31. B. Dave, M.D. Landis, L.E. Dobrolecki, M.F. Wu, X. Zhang, T.F. Westbrook, S.G. Hilsenbeck, D. Liu, M.T. Lewis, D.J. Tweardy, and J.C. Chang Selective small molecule stat3 inhibitor reduces breast cancer tumor-initiating cells and improves recurrence free survival in a human-xenograft model PLoS One 7 8 2012 e30207
32. L. Ghisolfi, A.C. Keates, X. Hu, D.K. Lee, and C.J. Li Ionizing radiation induces stemness in cancer cells PLoS One 7 8 2012 e43628
33. C. Lagadec, E. Vlashi, L. Della Donna, C. Dekmezian, and F. Pajonk Radiation-induced reprogramming of breast cancer cells Stem Cells 30 5 2012 833 844
34. Y. Kang, P.M. Siegel, W. Shu, M. Drobnjak, S.M. Kakonen, C. Cordon-Cardo, T.A. Guise, and J. Massague A multigenic program mediating breast cancer metastasis to bone Cancer Cell 3 6 2003 537 549 (Pubitemid 36808649)
35. J.J. Yin, K. Selander, J.M. Chirgwin, M. Dallas, B.G. Grubbs, R. Wieser, J. Massague, G.R. Mundy, and T.A. Guise TGF-beta signaling blockade inhibits pthrp secretion by breast cancer cells and bone metastases development J. Clin. Invest. 103 2 1999 197 206 (Pubitemid 29053137)
36. B.L. Eckhardt, P.A. Francis, B.S. Parker, and R.L. Anderson Strategies for the discovery and development of therapies for metastatic breast cancer Nat. Rev. Drug Discov. 11 6 2012 479 497
37. Y. Kawai, M. Kaidoh, and T. Ohhashi MDA-MB-231 produces atp-mediated icam-1-dependent facilitation of the attachment of carcinoma cells to human lymphatic endothelial cells Am. J. Physiol. Cell Physiol. 295 5 2008 C1123 C1132
38. E.J. Auzenne, J. Klostergaard, P.K. Mandal, W.S. Liao, Z. Lu, F. Gao, R.C. Bast Jr., F.M. Robertson, and J.S. McMurray A phosphopeptide mimetic prodrug targeting the sh2 domain of Stat3 inhibits tumor growth and angiogenesis J. Exp. Ther. Oncol. 10 2 2012 155 162
39. C.H. Li, J.X. Zhao, L. Sun, Z.Q. Yao, X.L. Deng, R. Liu, and X.Y. Liu AG490 inhibits NFATc1 expression and STAT3 activation during RANKL induced osteoclastogenesis Biochem. Biophys. Res. Commun. 435 4 2013 533 539
40. P.L. Doan, and J.P. Chute The vascular niche: home for normal and malignant hematopoietic stem cells Leukemia 26 1 2012 54 62
41. A.A. Rose, and P.M. Siegel Emerging therapeutic targets in breast cancer bone metastasis Future Oncol. 6 1 2010 55 74
42. K.M. Bussard, C.V. Gay, and A.M. Mastro The bone microenvironment in metastasis; what is special about bone? Cancer Metastasis Rev. 27 1 2008 41 55
43. D. Gao, N. Joshi, H. Choi, S. Ryu, M. Hahn, R. Catena, H. Sadik, P. Argani, P. Wagner, L.T. Vahdat, J.L. Port, B. Stiles, S. Sukumar, N.K. Altorki, S. Rafii, and V. Mittal Myeloid progenitor cells in the premetastatic lung promote metastases by inducing mesenchymal to epithelial transition Cancer Res. 72 6 2012 1384 1394
44. K.D. Simpson, D.J. Templeton, and J.V. Cross Macrophage migration inhibitory factor promotes tumor growth and metastasis by inducing myeloid-derived suppressor cells in the tumor microenvironment J. Immunol. 189 12 2012 5533 5540
45. J.A. Joyce, and J.W. Pollard Microenvironmental regulation of metastasis Nat. Rev. Cancer 9 4 2009 239 252